Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer begins Rs 1.3K...

    Bayer begins Rs 1.3K crore open offer process to buy up to 26 percent stake in Monsanto India

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-06-18T10:00:24+05:30  |  Updated On 18 Jun 2018 10:00 AM IST
    Bayer begins Rs 1.3K crore open offer process to buy up to 26 percent stake in Monsanto India

    German chemicals and pharma major Bayer group has launched the process for over Rs 1,300 crore open offer to acquire up to 26 percent additional stake in Monsanto India, following global acquisition of the US biotech major for USD 63 billion.


    Bayer AG, along with its Indian arm Bayer CropScience, has proposed to buy up to 44,88,315 shares, representing 26 percent of the fully diluted voting equity share capital of Monsanto India, according to a regulatory filing.


    The open offer was triggered as Bayer group has completed the USD 63 billion mega-deal to acquire Monsanto to create the world’s biggest agro-chemical and seed company. The deal resulted in Bayer group indirectly acquiring 72.14 percent stake in Monsanto India Ltd. Bayer group has fixed the open offer price at Rs 2,926.87 per share and the maximum size of the open offer will be Rs 1,313.67 crore, Monsanto India said in the filing to the BSE. The open offer will commence on July 27.



    On June 7, Bayer group closed the acquisition of Monsanto in a multi-billion dollar deal, which was announced in September 2016, after it got all necessary regulatory approvals from various countries including the US and India. Bayer group is present in India since 1896 and it has two divisions — crop science and pharmaceutical. The group has one listed entity in India — Bayer CropScience Ltd that posted a revenue from operation of nearly Rs 3,000 crore last fiscal.

    Bayer India had an annual revenue of 600 million euros (about Rs 4,700 crore) in 2017, Richard van der Merwe, the senior Bayer representative, South Asia, had said in January this year. Monsanto is selling genetically modified (GM) cotton seeds in India for more than a decade. With this deal, Monsanto would add seed business to Bayer’s already significant crop science and pharmaceutical business in India.







    Bayer AGbayer groupBayer-Monsanto dealIndiamonsanto buymonsanto cotton seedsmonsanto india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok